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Abstract Although it is still debated whether chronic
cerebro-spinal venous insufficiency (CCSVI) plays a role
in multiple sclerosis (MS) development, many patients
underwent endovascular treatment (ET) of CCSVI. The
objective of the study is to evaluate the outcome and safety
of ET in Italian MS patients. Italian MS centers that are
part of the Italian MS Study Group were all invited to
participate to this retrospective study. A structured ques-
tionnaire was used to collect detailed clinical data before
and after the ET. Data from 462 patients were collected in
33 centers. ET consisted of balloon dilatation (93 % of
cases) or stent application. The mean follow-up duration
after ET was 31 weeks. Mean EDSS remained unchanged
after ET (5.2 vs. 4.9), 144 relapses occurred in 98/462
cases (21 %), mainly in RR-MS patients. Fifteen severe
adverse events were recorded in 3.2 % of cases. Given the
risk of severe adverse events and the lack of objective
beneficial effects, our findings confirm that at present ET
should not be recommended to patients with MS.
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Introduction
Chronic cerebro-spinal venous insufficiency (CCSVI) has
been described as a condition of abnormal drainage of
venous blood due to stenosis or malformation of the
internal jugular and/or azygous veins [1, 2]. Using the
technique of transcranial color-coded duplex sonography
this abnormality was detected by Zamboni et al. [3, 4] in
100 % of patients with multiple sclerosis (MS): it was
therefore claimed to play a relevant pathogenetic role in
MS, causing an increased permeability of blood–brain
barrier in perivenular regions, local iron deposition, and
secondary multifocal inflammation.
No other study has confirmed the high frequency of
abnormality reported by Zamboni et al. and a great vari-
ability of CCSVI prevalence has been found in MS
patients, ranging from 0 to 92 % [5, 6]. Moreover, this
condition was also found in healthy subjects and in subjects
with other neurological disorders [5]. The lack of repro-
ducibility and specificity of the diagnostic procedures have
been adduced as findings against a pathogenetic role of
CCSVI in the development of MS [6, 7].
Despite the unclear relationship between CCSVI and
MS, many vascular surgeons or interventional radiologists
have started to dilate neck veins by balloons or applying
stents in MS patients, and many patients have decided to
undergo such procedures. Some open-label studies have
been published reporting a beneficial effect of endovascu-
lar treatment [8–15]. Nevertheless, side effects have also
been reported [9, 13]. Furthermore, FDA has produced a
document emphasizing the risks related to surgical inter-
ventions on neck veins [16].
In order to better evaluate the potential risks and benefits
of CCSVI correction in MS, the present multicenter survey
has been conducted in Italy to collect data from MS cases
that underwent endovascular treatment for CCSVI.
Materials and methods
Study design
This observational cohort study has been conducted within
the network of Italian MS centers, coordinated by the MS
Study Group of the Italian Society of Neurology. Thirty-
three MS centers participated to the study. The study
started in October 2011, after the design was presented
during the Italian Congress of Neurology, and data col-
lection was open until February 2012. It has been approved
by the Ethical Committee of the coordinating center.
During the visit to MS centers, patients were regularly
asked whether they underwent endovascular treatment for
MS, unless they spontaneously declared it, and consecu-
tively recruited. If the answer was positive, an ad hoc
questionnaire was filled, anonymised, and sent to the
coordinating center.
Questionnaire
A structured questionnaire was used to collect detailed
demographic and clinical data, including data on neuro-
logical status and MRI (if available) before, after the
intervention, and at the last available visit. Neurological
status was scored using Kurtzke FS and EDSS scales [17].
Other items of the questionnaire included patient’s sub-
jective clinical outcome, adverse events, and previous and
ongoing pharmacological treatments. On the whole, 28
items were included and analyzed.
Results
Data collected from 462 patients have been included in the
database and have been analyzed. Demographic and clin-
ical findings are summarized in Table 1.
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Endovascular CCSVI treatment consisted of balloon
dilatation in 93 % of cases and in stent application in 7 %.
The clinical outcome was assessed at a variable interval
after the intervention: the mean follow-up duration was
30.7 ± 36.1 weeks (median 24 weeks, I quartile 12 weeks, III
quartile 41 weeks). Results of EDSS score and of subjective
evaluation in relation to the length of follow-up are reported in
Table 2. The EDSS of the whole cohort at the last observation
was 5.2 ± 2.0, with a mild but not significant increase com-
pared to the baseline score (n.s. at paired at t test).
Data have also been analyzed in the subgroup of 242
patients (53 %) who reported that ET improved their
general-neurological condition: after a mean follow-up of
29.5 ± 34.6 weeks the final EDSS was 5.2 ± 2.0, starting
from a mean basal score of 4.9 ± 2.0 (n.s. at paired t test)
The distribution of cases according to EDSS scores,
before and after the intervention, is reported in Fig. 1 (n.s.
at Chi-square test). In the large majority of patients (281:
60.8 %) the final EDSS score was unchanged, it improved
by 0.5 in 24 (5.3 %) cases, by 1 point or more in 20 (4.4 %)
cases, it worsened by 0.5 in 76 (16.4 %) cases, and by 1
point or more in 61 (13.1 %) cases. No significant differ-
ence between pre- and post-ET EDSS score was found in
relation to clinical course (RR/SP/PP), gender, age (cut-off
was median age: 44 years), disability (cut-off was median
EDSS: 4.5) and disease duration (cut-off was median dis-
ease duration: 12 years) (n.s. at Chi-square test).
One hundred and forty-four relapses occurred in 98/462
(21 %) patients (69 RR patients, 25 SP patients, and 4 PP
patients): 58 relapses were observed in 26 out of 98
patients (26 %) who stopped the MS therapy after ET, and
50 relapses in 40 out of 189 patients (21 %) who continued
the therapy (p = 0.38) (Table 3); among those who expe-
rienced a relapse, the mean number of relapses per patient
was 1.4 ± 0.7 in the former and 1.2 ± 0.5 in the second
group (p = 0.402).
One hundred and seventy-one subjects underwent brain
MRI after the intervention (mean interval 28.8 ± 37.4 weeks).
Table 1 Demographic and clinical findings of MS patients who were submitted to endovascular treatment
No. F/M Age (years) Age at MS onset (years) Disease duration (years) Treated with
immunomodulators/
suppressants
EDSS
RR-MS 222 137/85 39.6 ± 8.6 27.0 ± 15.3 11.8 ± 8.7 169 (76.1 %) 3.7 ± 1.9
SP-MS 107 67/40 46.5 ± 9.0 29.4 ± 9.2 16.6 ± 6.1 87 (81.3 %) 6.2 ± 1.2
PP-MS 133 74/59 49.9 ± 11.0 36.9 ± 11.2 12.4 ± 6.3 31 (23.3 %) 6.0 ± 1.5
Overall 462 279/183 40.0 ± 10.0 29.6 ± 11.9 13.6 ± 7.0 287 (62.1 %) 4.9 ± 2.0
Table 2 Clinical outcome after ET in the whole cohort and in subgroups of patients according to the length of follow-up
Follow-up duration
(months)
No. of pts EDSS Subjective evaluation
Baseline At follow-up Improved (%) Stable (%) Worsened (%)
\3 121 5.1 ± 2.0 5.2 ± 2.0* 55.4 33.0 11.6
3–6 93 5.1 ± 1.9 5.2 ± 2.0* 51.6 34.5 13.9
[6 248 4.8 ± 2.1 5.1 ± 2.1* 48.3 42.0 9.7
Whole cohort 462 4.9 ± 2.0 5.2 ± 2.0* 52.5 36.5 11.0
* n.s. at paired at t test
Fig. 1 Distribution of patients
(%) according to EDSS
(\2, 2–3.5, 4–5.5, [5.5) before
and after endovascular
treatment (ET)
(n.s. at Chi-square test)
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Active lesions (i.e., contrast-enhancing or new T2-hyperin-
tense) were observed in 61 (35.7 %) of these patients.
Adverse events were recorded in 50 patients (13 %):
they were mild in 35 patients (7.5 %) and mainly consisted
of nausea, headache, cutaneous rash or other skin reactions,
and inguinal haematoma.
Severe adverse events were recorded in 15 patients
(3.2 %). They are summarized in Table 4, and are more
extensively described elsewhere [18].
Discussion
We are aware of the relevant limitations of this study,
namely the observational design, the lack of an untreated
control group, the lack of a blinded evaluation, the possible
bias of patient selection. Nevertheless, our data describe
the condition of MS patients who underwent endovascular
treatment for CCSVI as observed in the ‘‘everyday clinical
life’’ of Italian MS centers. Furthermore, to our knowledge
this is the largest case record of MS patients treated for
CCSVI ever published, and no randomized controlled trial
is at present available.
We did not find a significant positive clinical outcome
after ET in our patients. In the whole cohort as well as in
the subgroup of ‘‘subjectively improved’’ patients the mean
EDSS was unchanged at the last visit. Due to the unblin-
ding of the observer this finding could not reliably reflect
the real impact of endovascular procedure; however, using
the occurrence of relapses as clinical end-point, that is a
less subjective finding, 21 % of the whole cohort devel-
oped a relapse in a relatively short interval after the
intervention. The discontinuation of treatment for MS
increased the risk of relapses, but they also occurred in
patients without any previous treatment as well as in those
who continued to take it. Moreover, many subjects pre-
sented an MRI reactivation of MS with the development of
new or enhancing lesions.
More than 50 % of cases of our cohort were affected by
primary (133, 28.8 %) or secondary progressive (107,
23.1 %) MS. These patients frequently experience a neg-
ative evolution of the disease, without a positive effect of
pharmacological treatments: due to media pressure, ET has
been proposed, and perceived, as a possible therapeutic
solution, generating many expectations. About 50 % of
cases of the whole cohort reported a subjective clinical
benefit, but their EDSS remained unchanged after the
treatment. The clinical outcome did not differ when data
were analyzed in relation to clinical course, disease dura-
tion, gender, age.
To conclude, the results of our study do not show an
outstanding beneficial effect of endovascular treatment in
MS. Only a double-blind, placebo-controlled trial can give
a definite answer about the actual impact of CCSVI
endovascular treatment on MS evolution, once proven that
this treatment is justified because of the unclear relation-
ship between CCSVI and MS. A large multicenter study is
in progress in Italy to evaluate the frequency of CCSVI in
MS, healthy controls and other neurological degenerative
disorders. On the other hand, the same methodological
limitations we previously mentioned—mainly the lack of a
control group and the unblinded evaluation—do charac-
terize the studies that have reported positive results in
terms of ET efficacy [12, 15, 16].
The occurrence of adverse events, namely jugular throm-
bosis, in 2–55 % of cases, more rarely vessel dissection,
arrhythmias, vein breaking, stress-induced cardiomyopathy
have been reported in previous studies [10, 11, 13]. FDA has
recently pointed out the possible risks related to CCSVI en-
dovascular treatment [16], having received reports of one
patient who died from brain hemorrhage and another one who
suffered permanent paralysis from a stroke after CCSVI
Table 3 Distribution of relapses after ET in relation to treatment for
MS
No. Patients (%)
with relapses
No. of relapses
(relapses per patient)
Not treated 172 32 (18.3) 36 (1.1)
Treated
Stopped after ET 98 26 (26.5) 58 (1.4)
Continued after ET 189 40 (21.1) 50 (1.2)
Table 4 Severe adverse events occurring in MS patients who were
submitted to endovascular treatment
# Side effect Onset from
intervention
EDSS
change
1 Jugular thrombosis 48 h No
2 Jugular thrombosis 7 days 2.5–3.5
3 Jugular thrombosis 30 days No
4 Jugular thrombosis 30 days No
5 Jugular thrombosis 6 weeks No
6 Jugular thrombosis 10 weeks 5–6
7 Jugular thrombosis 41 weeks No
8 Paroxysmal atrial fibrillation 24 h No
9 Tetraventricular hydrocephalus 48 h 6–6.5
10 Stroke 12 weeks 7.5–8.5
11 Status epilepticus 8 weeks 4.5–9.5
12 Aspiration pneumonia 7 days 7.5–9.0
13 Hypertension and tachycardia
post sternotomy
30 days No
14 Severe bleeding from a bedsore 15 days No
15 Myocardial infarction 10 weeks Death
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treatment. Other reported serious complications of the CCSVI
procedure including stent migration from the original loca-
tion, venous injury, brain deep vein thrombosis, cranial
nerves damage, and abdominal bleeding [16].
In our study, mild adverse events were observed in 35
patients; severe adverse events occurred in 15 patients after
a variable interval from ET, including a patient who died
because of myocardial infarction 10 weeks after ET: cases
are more extensively presented in another paper [18].
To conclude, our results, observed in a large cohort of
Italian MS patients, support the view that endovascular
treatment can expose patients to severe, albeit relatively
rare adverse events. Moreover, no clear beneficial clinical
effect has been observed in our cohort after ET: the EDSS
was unchanged after the procedure, relapses did not reduce,
some patients presented new MRI lesions. Finally, the role
of CCSVI has on MS pathogenesis has not been confirmed
[6, 7]: the recent results of the largest cohort ever studied
have shown that the prevalence of CCSVI is very low in
MS patients, identical to that observed in normal subjects
and in patients with other neurological disorders (Comi
et al., paper in preparation). At present these findings
confirm that CCSVI treatment should not be recommended
to MS patients before additional studies will have better
defined the real prevalence of CCSVI in MS and the ben-
efit/risk profile of this treatment.
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